title: The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
abstract: We studied the impact of cytogenetics and kind of induction/consolidation therapy on 848 adult acute myeloid leukemia (AML) patients (age 15-83). The patients received three types of induction/consolidation regimen: standard (daunorubicin and cytosine arabinoside (3/7); two cycles); intensive (idarubicin, cytosine arabinoside and etoposide (ICE), plus mitoxantrone and intermediate-dose Ara-C (NOVIA)); and low-dose (low-dose cytosine arabinoside). CR patients under 60 years of age, if an HLA-identical donor was available received allogeneic stem cell transplantation (allo-SCT); otherwise, as part of the program, they underwent autologous (auto)-SCT. CR rates significantly associated with 'favorable' (inv(16), t(8;21)), 'intermediate' ('no abnormality', abn(11q23), +8, del(7q)) and 'unfavorable' (del (5q), -7, abn(3)(q21q26), t(6;9), 'complex' (more than three unrelated cytogenetic abnormalities)) karyotypes (88% vs 65% vs 36%, respectively; P = 0.0001). These trends were confirmed in all age groups. On therapeutic grounds, intensive induction did not determine significant increases of CR rates in any of the considered groups, with respect to standard induction. Low-dose induction was associated with significantly lower CR rates. Considering disease-free survival (DFS), multivariate analysis of the factors examined (including karyotype grouping) showed that only age > 60 years significantly affected outcome. However, in cases where intensive induction was adopted, 'favorable' karyotype was significantly related to longer DFS (P = 0.04). This was mainly due to the favorable outcome of t(8;21) patients treated with intensive induction. Patients receiving allo-SCT had significantly longer DFS (P = 0.005); in particular, allo-SCT significantly improved DFS in the 'favorable' and 'intermediate' groups (P = 0.04 and P = 0.048, respectively). In conclusion our study could provide some guidelines for AML therapy: (1) patients in the 'favorable' karyotype group seem to have a longer DFS when treated with an intensive induction/consolidation regimen, adopted before auto-SCT instead of standard induction; this underlines the importance of reinforcement of chemotherapy, not necessarily based on repeated high-dose AraC cycles. Allo-SCT, independently of induction/consolidation therapy, should be considered an alternative treatment; (2) patients in the 'intermediate' karyotype group should receive allo-SCT; (3) patients in the 'unfavorable' karyotype group should be treated using investigational chemotherapy, considering that even allo-SCT cannot provide a significantly longer DFS, but only a trend to a better prognosis.
authors: Seràgnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna, Italy.
authors: G
authors: G
authors: Visani
authors: P
authors: P
authors: Bernasconi
authors: M
authors: M
authors: Boni
authors: G L
authors: GL
authors: Castoldi
authors: S
authors: S
authors: Ciolli
authors: M
authors: M
authors: Clavio
authors: M C
authors: MC
authors: Cox
authors: A
authors: A
authors: Cuneo
authors: G
authors: G
authors: Del Poeta
authors: D
authors: D
authors: Dini
authors: D
authors: D
authors: Falzetti
authors: R
authors: R
authors: Fanin
authors: M
authors: M
authors: Gobbi
authors: A
authors: A
authors: Isidori
authors: F
authors: F
authors: Leoni
authors: V
authors: V
authors: Liso
authors: M
authors: M
authors: Malagola
authors: G
authors: G
authors: Martinelli
authors: C
authors: C
authors: Mecucci
authors: P P
authors: PP
authors: Piccaluga
authors: M C
authors: MC
authors: Petti
authors: R
authors: R
authors: Rondelli
authors: D
authors: D
authors: Russo
authors: M
authors: M
authors: Sessarego
authors: G
authors: G
authors: Specchia
authors: N
authors: N
authors: Testoni
authors: G
authors: G
authors: Torelli
authors: F
authors: F
authors: Mandelli
authors: S
authors: S
authors: Tura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D007446:Chromosome Inversion; D002877:Chromosomes, Human / Q000648:ultrastructure; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006529:Hepatomegaly / Q000453:epidemiology; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D013163:Splenomegaly / Q000453:epidemiology; D016019:Survival Analysis; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; D015255:Idarubicin; D003630:Daunorubicin